Serum IL-5 and IFN-γ Are Novel Predictive Biomarkers for Anti-PD-1 Treatment in NSCLC and GC Patients

Figure 4

Serum IL-5 and IFN-γ levels associated with progression-free survival in metastatic NSCLC patients treated with anti-PD-1 mAbs. Patients were stratified into two subgroups (decrease and increase) based on IL-5 or IFN-γ levels at BL. Kaplan-Meier plots depict PFS differences between IL-5 (a) or IFN-γ (b) levels. Data were analyzed by the log-rank (Mantel-Cox) test.

(a)

(b)